RXi Pharmaceuticals (RXII) Getting Somewhat Favorable Press Coverage, Study Shows
News coverage about RXi Pharmaceuticals (NASDAQ:RXII) has been trending somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. RXi Pharmaceuticals earned a news impact score of 0.23 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.0917270273167 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
RXi Pharmaceuticals (NASDAQ:RXII) opened at $0.56 on Friday. RXi Pharmaceuticals has a twelve month low of $0.32 and a twelve month high of $1.12. The company has a market capitalization of $13.17, a P/E ratio of -0.51 and a beta of 1.38.
RXi Pharmaceuticals (NASDAQ:RXII) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.11) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.11). During the same period in the previous year, the firm earned ($0.34) earnings per share.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/rxi-pharmaceuticals-rxii-getting-somewhat-favorable-press-coverage-study-shows/1789639.html.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.
Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.